Drugs / Autologous Menstrual Blood Stem Cells
Autologous Menstrual Blood Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05703308 | Jun 2020 → Sep 2021 | female infertility, ovarian dysfunction | Avicenna Research Institute | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Menstrual Blood Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703308 ↗ |
| Known as | MenSCs | “Our previous research has demonstrated that menstrual blood-derived-mesenchymal stromal cells (MenSCs) injected into the ovaries of women with POR can increase pregnancy rates.” PMID 37968668 ↗ Nov 2023 |
| Known as | menstrual blood-derived-mesenchymal stromal cells | “Our previous research has demonstrated that menstrual blood-derived-mesenchymal stromal cells (MenSCs) injected into the ovaries of women with POR can increase pregnancy rates.” PMID 37968668 ↗ Nov 2023 |
| Action | Restore | “Men-MSCs could be considered as a potential treatment to restore the fertility capability of POR women.” NCT05703308 ↗ |
| Route | Other | “150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia” NCT05703308 ↗ |